COPD fixed-dose combo enhances lung function

Because lung function can be substantially reduced by the time most chronic obstructive pulmonary disease (COPD) patients first see a physician, maintenance treatment should be considered at the time of diagnosis, according to new data analyses presented at the American Thoracic Society (ATS) 2015 International Conference.

Related: [BLOG]: Best Practices between formulary managers and pharmacists to address challenges in COPD readmissions

In the pivotal phase 3 TONADO 1 and 2 studies, which explored the efficacy and safety of investigational tiotropium/olodaterol delivered via the Respimat inhaler for COPD, compared to the individual components alone, tiotropium/olodaterol Respimat demonstrated a statistically significant improvement in lung function compared to tiotropium and olodaterol alone for COPD patients across all stages of the disease (A-D).

The analyses presented at ATS showed that in comparison to tiotropium Respimat 5 μg and olodaterol Respimat 5 μg, tiotropium/olodaterol Respimat 5/5 μg:

• Improved lung function, as measured by trough FEV₁, in patients who were untreated and/or previously treated with maintenance bronchodilator therapy

• Provided statistically significant improvements in lung function, as measured by trough FEV₁ and FEV₁AUC_0-3, in patients across all COPD stages

• Demonstrated statistically significant improvement of lung function irrespective of whether patients were taking inhaled corticosteroids (ICS) at the start of the trials

A safety analysis found tiotropium/olodaterol Respimat 5/5 μg had a comparable safety profile to tiotropium Respimat 5 μg or olodaterol Respimat 5 μg alone.

 

Internal server error